Divya andy (17 resultados)

- Tapa blanda
Librería: California Books, Miami, FL, Estados Unidos de AmericaCalifornia Books
Contactar con el vendedorVendedor de 5 estrellasCondición: Nuevo
EUR 253,26
Envío por EUR 2,72Se envía dentro de Estados Unidos de AmericaCantidad disponible: Más de 20 disponibles
Condición: New.

- Tapa dura
Librería: California Books, Miami, FL, Estados Unidos de AmericaCalifornia Books
Contactar con el vendedorVendedor de 5 estrellasCondición: Nuevo
EUR 299,99
Envío por EUR 2,72Se envía dentro de Estados Unidos de AmericaCantidad disponible: Más de 20 disponibles
Condición: New.

- Tapa dura
Librería: Home-set, Mannheim, AlemaniaHome-set
Contactar con el vendedorVendedor de 5 estrellasCondición: Nuevo
EUR 372,25
Envío por EUR 60,98Se envía de Alemania a Estados Unidos de AmericaCantidad disponible: 2 disponibles
Gebundene Ausgabe. Condición: Neu. Gene and cell therapy is entering a new phase, one where artificial intelligence is bringing precision and predictability to editing systems that were once largely trial-and-error. From CRISPR-Cas genome editing to emerging techniques like epigenome modulation and mitochondrial genome correction, machine learning and deep learning are increasingly guiding how these tools are designed and scaled. AI is helping minimize off-target effects, improve manufacturing predictability, and build in the kind of explainability and bias mitigation that safety and regulatory approval demand. As these technologies move closer to widespread clinical use, the field needs a framework that ties computational innovation directly to therapeutic application, rather than treating AI and biomedicine as separate conversations. This convergence of computational innovation and biological engineering marks one of the most consequential shifts in modern therapeutic science. AI-Driven Innovations in Genome, Epigenome, and Mitochondrial Therapies provides state-of-the-art, data-driven methodologies for designing, optimizing, and validating safer, more precise, and scalable gene and cell therapies. By connecting concrete biomedical applications with benchmarked computational pipelines and structured frameworks for transparent, accountable AI governance, this book equips researchers and practitioners to navigate discovery, preclinical validation, clinical translation, and lifecycle risk management. Covering topics such as genome-enabled precision wound care, mitochondrial mutation detection, and mitochondrial editing, this book is an excellent academic resource for graduate and doctoral students, biomedical researchers, AI and machine learning specialists, bioinformaticians, regulatory affairs professionals, policymakers, and more. Sprache: Englisch Gewicht in Gramm: 1119.…

- Tapa blanda
- Impresión bajo demanda
Librería: PBShop.store UK, Fairford, GLOS, Reino UnidoPBShop.store UK
Contactar con el vendedorVendedor de 5 estrellasCondición: Nuevo
EUR 207,55
Envío por EUR 7,04Se envía de Reino Unido a Estados Unidos de AmericaCantidad disponible: Más de 20 disponibles
PAP. Condición: New. New Book. Delivered from our UK warehouse in 4 to 14 business days. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000.

- Tapa blanda
- Impresión bajo demanda
Librería: PBShop.store US, Wood Dale, IL, Estados Unidos de AmericaPBShop.store US
Contactar con el vendedorVendedor de 5 estrellasCondición: Nuevo
EUR 219,24
Gastos de envío gratisSe envía dentro de Estados Unidos de AmericaCantidad disponible: Más de 20 disponibles
PAP. Condición: New. New Book. Shipped from UK. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000.

- Tapa blanda
- Impresión bajo demanda
Librería: Grand Eagle Retail, Bensenville, IL, Estados Unidos de AmericaGrand Eagle Retail
Contactar con el vendedorVendedor de 5 estrellasCondición: Nuevo
EUR 254,20
Gastos de envío gratisSe envía dentro de Estados Unidos de AmericaCantidad disponible: 1 disponible
Paperback. Condición: new. Paperback. Gene and cell therapy is entering a new phase, one where artificial intelligence is bringing precision and predictability to editing systems that were once largely trial-and-error. From CRISPR-Cas genome editing to emerging techniques like epigenome modulation and mitochondrial genome correction, machine learning and deep learning are increasingly guiding how these tools are designed and scaled. AI is helping minimize off-target effects, improve manufacturing predictability, and build in the kind of explainability and bias mitigation that safety and regulatory approval demand. As these technologies move closer to widespread clinical use, the field needs a framework that ties computational innovation directly to therapeutic application, rather than treating AI and biomedicine as separate conversations. This convergence of computational innovation and biological engineering marks one of the most consequential shifts in modern therapeutic science. AI-Driven Innovations in Genome, Epigenome, and Mitochondrial Therapies provides state-of-the-art, data-driven methodologies for designing, optimizing, and validating safer, more precise, and scalable gene and cell therapies. By connecting concrete biomedical applications with benchmarked computational pipelines and structured frameworks for transparent, accountable AI governance, this book equips researchers and practitioners to navigate discovery, preclinical validation, clinical translation, and lifecycle risk management. Covering topics such as genome-enabled precision wound care, mitochondrial mutation detection, and mitochondrial editing, this book is an excellent academic resource for graduate and doctoral students, biomedical researchers, AI and machine learning specialists, bioinformaticians, regulatory affairs professionals, policymakers, and more. This item is printed on demand. Shipping may be from multiple locations in the US or from the UK, depending on stock availability.…

- Tapa dura
- Impresión bajo demanda
Librería: PBShop.store UK, Fairford, GLOS, Reino UnidoPBShop.store UK
Contactar con el vendedorVendedor de 5 estrellasCondición: Nuevo
EUR 245,23
Envío por EUR 8,10Se envía de Reino Unido a Estados Unidos de AmericaCantidad disponible: Más de 20 disponibles
HRD. Condición: New. New Book. Delivered from our UK warehouse in 4 to 14 business days. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000.

- Tapa dura
- Impresión bajo demanda
Librería: PBShop.store US, Wood Dale, IL, Estados Unidos de AmericaPBShop.store US
Contactar con el vendedorVendedor de 5 estrellasCondición: Nuevo
EUR 259,28
Gastos de envío gratisSe envía dentro de Estados Unidos de AmericaCantidad disponible: Más de 20 disponibles
HRD. Condición: New. New Book. Shipped from UK. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000.

- Tapa blanda
- Impresión bajo demanda
Librería: CitiRetail, Stevenage, Reino UnidoCitiRetail
Contactar con el vendedorVendedor de 5 estrellasCondición: Nuevo
EUR 217,92
Envío por EUR 44,36Se envía de Reino Unido a Estados Unidos de AmericaCantidad disponible: 1 disponible
Paperback. Condición: new. Paperback. Gene and cell therapy is entering a new phase, one where artificial intelligence is bringing precision and predictability to editing systems that were once largely trial-and-error. From CRISPR-Cas genome editing to emerging techniques like epigenome modulation and mitochondrial genome correction, machine learning and deep learning are increasingly guiding how these tools are designed and scaled. AI is helping minimize off-target effects, improve manufacturing predictability, and build in the kind of explainability and bias mitigation that safety and regulatory approval demand. As these technologies move closer to widespread clinical use, the field needs a framework that ties computational innovation directly to therapeutic application, rather than treating AI and biomedicine as separate conversations. This convergence of computational innovation and biological engineering marks one of the most consequential shifts in modern therapeutic science. AI-Driven Innovations in Genome, Epigenome, and Mitochondrial Therapies provides state-of-the-art, data-driven methodologies for designing, optimizing, and validating safer, more precise, and scalable gene and cell therapies. By connecting concrete biomedical applications with benchmarked computational pipelines and structured frameworks for transparent, accountable AI governance, this book equips researchers and practitioners to navigate discovery, preclinical validation, clinical translation, and lifecycle risk management. Covering topics such as genome-enabled precision wound care, mitochondrial mutation detection, and mitochondrial editing, this book is an excellent academic resource for graduate and doctoral students, biomedical researchers, AI and machine learning specialists, bioinformaticians, regulatory affairs professionals, policymakers, and more. This item is printed on demand. Shipping may be from our UK warehouse or from our Australian or US warehouses, depending on stock availability.…

- Tapa dura
- Impresión bajo demanda
Librería: Grand Eagle Retail, Bensenville, IL, Estados Unidos de AmericaGrand Eagle Retail
Contactar con el vendedorVendedor de 5 estrellasCondición: Nuevo
EUR 296,88
Gastos de envío gratisSe envía dentro de Estados Unidos de AmericaCantidad disponible: 1 disponible
Hardcover. Condición: new. Hardcover. Gene and cell therapy is entering a new phase, one where artificial intelligence is bringing precision and predictability to editing systems that were once largely trial-and-error. From CRISPR-Cas genome editing to emerging techniques like epigenome modulation and mitochondrial genome correction, machine learning and deep learning are increasingly guiding how these tools are designed and scaled. AI is helping minimize off-target effects, improve manufacturing predictability, and build in the kind of explainability and bias mitigation that safety and regulatory approval demand. As these technologies move closer to widespread clinical use, the field needs a framework that ties computational innovation directly to therapeutic application, rather than treating AI and biomedicine as separate conversations. This convergence of computational innovation and biological engineering marks one of the most consequential shifts in modern therapeutic science. AI-Driven Innovations in Genome, Epigenome, and Mitochondrial Therapies provides state-of-the-art, data-driven methodologies for designing, optimizing, and validating safer, more precise, and scalable gene and cell therapies. By connecting concrete biomedical applications with benchmarked computational pipelines and structured frameworks for transparent, accountable AI governance, this book equips researchers and practitioners to navigate discovery, preclinical validation, clinical translation, and lifecycle risk management. Covering topics such as genome-enabled precision wound care, mitochondrial mutation detection, and mitochondrial editing, this book is an excellent academic resource for graduate and doctoral students, biomedical researchers, AI and machine learning specialists, bioinformaticians, regulatory affairs professionals, policymakers, and more. This item is printed on demand. Shipping may be from multiple locations in the US or from the UK, depending on stock availability.…

- Tapa dura
- Impresión bajo demanda
Librería: CitiRetail, Stevenage, Reino UnidoCitiRetail
Contactar con el vendedorVendedor de 5 estrellasCondición: Nuevo
EUR 256,82
Envío por EUR 44,36Se envía de Reino Unido a Estados Unidos de AmericaCantidad disponible: 1 disponible
Hardcover. Condición: new. Hardcover. Gene and cell therapy is entering a new phase, one where artificial intelligence is bringing precision and predictability to editing systems that were once largely trial-and-error. From CRISPR-Cas genome editing to emerging techniques like epigenome modulation and mitochondrial genome correction, machine learning and deep learning are increasingly guiding how these tools are designed and scaled. AI is helping minimize off-target effects, improve manufacturing predictability, and build in the kind of explainability and bias mitigation that safety and regulatory approval demand. As these technologies move closer to widespread clinical use, the field needs a framework that ties computational innovation directly to therapeutic application, rather than treating AI and biomedicine as separate conversations. This convergence of computational innovation and biological engineering marks one of the most consequential shifts in modern therapeutic science. AI-Driven Innovations in Genome, Epigenome, and Mitochondrial Therapies provides state-of-the-art, data-driven methodologies for designing, optimizing, and validating safer, more precise, and scalable gene and cell therapies. By connecting concrete biomedical applications with benchmarked computational pipelines and structured frameworks for transparent, accountable AI governance, this book equips researchers and practitioners to navigate discovery, preclinical validation, clinical translation, and lifecycle risk management. Covering topics such as genome-enabled precision wound care, mitochondrial mutation detection, and mitochondrial editing, this book is an excellent academic resource for graduate and doctoral students, biomedical researchers, AI and machine learning specialists, bioinformaticians, regulatory affairs professionals, policymakers, and more. This item is printed on demand. Shipping may be from our UK warehouse or from our Australian or US warehouses, depending on stock availability.…

- Tapa blanda
- Impresión bajo demanda
Librería: AussieBookSeller, Truganina, VIC, AustraliaAussieBookSeller
Contactar con el vendedorVendedor de 5 estrellasCondición: Nuevo
EUR 281,44
Envío por EUR 33,57Se envía de Australia a Estados Unidos de AmericaCantidad disponible: 1 disponible
Paperback. Condición: new. Paperback. Gene and cell therapy is entering a new phase, one where artificial intelligence is bringing precision and predictability to editing systems that were once largely trial-and-error. From CRISPR-Cas genome editing to emerging techniques like epigenome modulation and mitochondrial genome correction, machine learning and deep learning are increasingly guiding how these tools are designed and scaled. AI is helping minimize off-target effects, improve manufacturing predictability, and build in the kind of explainability and bias mitigation that safety and regulatory approval demand. As these technologies move closer to widespread clinical use, the field needs a framework that ties computational innovation directly to therapeutic application, rather than treating AI and biomedicine as separate conversations. This convergence of computational innovation and biological engineering marks one of the most consequential shifts in modern therapeutic science. AI-Driven Innovations in Genome, Epigenome, and Mitochondrial Therapies provides state-of-the-art, data-driven methodologies for designing, optimizing, and validating safer, more precise, and scalable gene and cell therapies. By connecting concrete biomedical applications with benchmarked computational pipelines and structured frameworks for transparent, accountable AI governance, this book equips researchers and practitioners to navigate discovery, preclinical validation, clinical translation, and lifecycle risk management. Covering topics such as genome-enabled precision wound care, mitochondrial mutation detection, and mitochondrial editing, this book is an excellent academic resource for graduate and doctoral students, biomedical researchers, AI and machine learning specialists, bioinformaticians, regulatory affairs professionals, policymakers, and more. This item is printed on demand. Shipping may be from our Sydney, NSW warehouse or from our UK or US warehouse, depending on stock availability.…

- Tapa blanda
- Impresión bajo demanda
Librería: AHA-BUCH GmbH, Einbeck, AlemaniaAHA-BUCH GmbH
Contactar con el vendedorVendedor de 5 estrellasCondición: Nuevo
EUR 294,43
Envío por EUR 35,00Se envía de Alemania a Estados Unidos de AmericaCantidad disponible: 2 disponibles
Taschenbuch. Condición: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - Gene and cell therapy is entering a new phase, one where artificial intelligence is bringing precision and predictability to editing systems that were once largely trial-and-error. From CRISPR-Cas genome editing to emerging techniques like epigenome modulation and mitochondrial genome correction, machine learning and deep learning are increasingly guiding how these tools are designed and scaled. AI is helping minimize off-target effects, improve manufacturing predictability, and build in the kind of explainability and bias mitigation that safety and regulatory approval demand. As these technologies move closer to widespread clinical use, the field needs a framework that ties computational innovation directly to therapeutic application, rather than treating AI and biomedicine as separate conversations. This convergence of computational innovation and biological engineering marks one of the most consequential shifts in modern therapeutic science. AI-Driven Innovations in Genome, Epigenome, and Mitochondrial Therapies provides state-of-the-art, data-driven methodologies for designing, optimizing, and validating safer, more precise, and scalable gene and cell therapies. By connecting concrete biomedical applications with benchmarked computational pipelines and structured frameworks for transparent, accountable AI governance, this book equips researchers and practitioners to navigate discovery, preclinical validation, clinical translation, and lifecycle risk management. Covering topics such as genome-enabled precision wound care, mitochondrial mutation detection, and mitochondrial editing, this book is an excellent academic resource for graduate and doctoral students, biomedical researchers, AI and machine learning specialists, bioinformaticians, regulatory affairs professionals, policymakers, and more.…

- Tapa blanda
- Impresión bajo demanda
Librería: preigu, Osnabrück, Alemaniapreigu
Contactar con el vendedorVendedor de 5 estrellasCondición: Nuevo
EUR 275,60
Envío por EUR 70,00Se envía de Alemania a Estados Unidos de AmericaCantidad disponible: 5 disponibles
Taschenbuch. Condición: Neu. AI-Driven Innovations in Genome, Epigenome, and Mitochondrial Therapies | Divya Andy (u. a.) | Taschenbuch | Englisch | 2026 | IGI GLOBAL SCIENTIFIC PUBLISHING | EAN 9798260001622 | Verantwortliche Person für die EU: Libri GmbH, Europaallee 1, 36244 Bad Hersfeld, gpsr[at]libri[dot]de | Anbieter: preigu Print on Demand. …

- Tapa dura
- Impresión bajo demanda
Librería: AussieBookSeller, Truganina, VIC, AustraliaAussieBookSeller
Contactar con el vendedorVendedor de 5 estrellasCondición: Nuevo
EUR 329,08
Envío por EUR 33,57Se envía de Australia a Estados Unidos de AmericaCantidad disponible: 1 disponible
Hardcover. Condición: new. Hardcover. Gene and cell therapy is entering a new phase, one where artificial intelligence is bringing precision and predictability to editing systems that were once largely trial-and-error. From CRISPR-Cas genome editing to emerging techniques like epigenome modulation and mitochondrial genome correction, machine learning and deep learning are increasingly guiding how these tools are designed and scaled. AI is helping minimize off-target effects, improve manufacturing predictability, and build in the kind of explainability and bias mitigation that safety and regulatory approval demand. As these technologies move closer to widespread clinical use, the field needs a framework that ties computational innovation directly to therapeutic application, rather than treating AI and biomedicine as separate conversations. This convergence of computational innovation and biological engineering marks one of the most consequential shifts in modern therapeutic science. AI-Driven Innovations in Genome, Epigenome, and Mitochondrial Therapies provides state-of-the-art, data-driven methodologies for designing, optimizing, and validating safer, more precise, and scalable gene and cell therapies. By connecting concrete biomedical applications with benchmarked computational pipelines and structured frameworks for transparent, accountable AI governance, this book equips researchers and practitioners to navigate discovery, preclinical validation, clinical translation, and lifecycle risk management. Covering topics such as genome-enabled precision wound care, mitochondrial mutation detection, and mitochondrial editing, this book is an excellent academic resource for graduate and doctoral students, biomedical researchers, AI and machine learning specialists, bioinformaticians, regulatory affairs professionals, policymakers, and more. This item is printed on demand. Shipping may be from our Sydney, NSW warehouse or from our UK or US warehouse, depending on stock availability.…

- Tapa dura
- Impresión bajo demanda
Librería: preigu, Osnabrück, Alemaniapreigu
Contactar con el vendedorVendedor de 5 estrellasCondición: Nuevo
EUR 317,35
Envío por EUR 70,00Se envía de Alemania a Estados Unidos de AmericaCantidad disponible: 5 disponibles
Buch. Condición: Neu. AI-Driven Innovations in Genome, Epigenome, and Mitochondrial Therapies | Divya Andy (u. a.) | Buch | Englisch | 2026 | IGI GLOBAL SCIENTIFIC PUBLISHING | EAN 9798260001615 | Verantwortliche Person für die EU: Libri GmbH, Europaallee 1, 36244 Bad Hersfeld, gpsr[at]libri[dot]de | Anbieter: preigu Print on Demand.…

- Tapa dura
- Impresión bajo demanda
Librería: AHA-BUCH GmbH, Einbeck, AlemaniaAHA-BUCH GmbH
Contactar con el vendedorVendedor de 5 estrellasCondición: Nuevo
EUR 346,30
Envío por EUR 42,83Se envía de Alemania a Estados Unidos de AmericaCantidad disponible: 2 disponibles
Buch. Condición: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - Gene and cell therapy is entering a new phase, one where artificial intelligence is bringing precision and predictability to editing systems that were once largely trial-and-error. From CRISPR-Cas genome editing to emerging techniques like epigenome modulation and mitochondrial genome correction, machine learning and deep learning are increasingly guiding how these tools are designed and scaled. AI is helping minimize off-target effects, improve manufacturing predictability, and build in the kind of explainability and bias mitigation that safety and regulatory approval demand. As these technologies move closer to widespread clinical use, the field needs a framework that ties computational innovation directly to therapeutic application, rather than treating AI and biomedicine as separate conversations. This convergence of computational innovation and biological engineering marks one of the most consequential shifts in modern therapeutic science. AI-Driven Innovations in Genome, Epigenome, and Mitochondrial Therapies provides state-of-the-art, data-driven methodologies for designing, optimizing, and validating safer, more precise, and scalable gene and cell therapies. By connecting concrete biomedical applications with benchmarked computational pipelines and structured frameworks for transparent, accountable AI governance, this book equips researchers and practitioners to navigate discovery, preclinical validation, clinical translation, and lifecycle risk management. Covering topics such as genome-enabled precision wound care, mitochondrial mutation detection, and mitochondrial editing, this book is an excellent academic resource for graduate and doctoral students, biomedical researchers, AI and machine learning specialists, bioinformaticians, regulatory affairs professionals, policymakers, and more.…